MN553 UNIT 5 QUIZ / MN 553 UNIT 5 QUIZ (NEWEST 2020): PHARMACOLOGY: KAPLAN UNIVERSITY
QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines |
Graded A+...
CORE DOMAINS
Pharmacotherapy of Psychiatric Disorders: Antidepressants, Anxiolytics, and Mood Stabilizers
Pharmacology of the Central Nervous System: Antipsychotics and Agents for Neurodegenerative Disorders
Pain Management: Opioid and Non-Opioid Analgesics, Adjuvant Analgesics, and Substance Use Disorders
Pharmacotherapy of Neurologic Disorders: Antiepileptics, Antimigraine Agents, and Movement Disorders
Special Populations: Pediatric and Geriatric Psychopharmacology
Toxicology, Overdose Management, and Substance Use Disorder Pharmacotherapy
Pharmacokinetic Drug Interactions in Psychopharmacology and Neurology
Principles of Monitoring and Managing Adverse Effects of CNS-Active Drugs
INTRODUCTION
This comprehensive assessment is designed to evaluate advanced pharmacotherapeutic knowledge and clinical
reasoning skills essential for the safe and effective management of psychiatric and neurologic conditions in
primary and specialty care. The examination challenges candidates to apply principles of neuropharmacology,
receptor theory, and evidence-based prescribing to complex clinical scenarios involving depression, anxiety,
psychosis, epilepsy, pain, and substance use disorders. Through scenario-based testing, candidates must
,demonstrate the ability to select first-line pharmacotherapy, anticipate and manage serious adverse drug reactions
including serotonin syndrome and neuroleptic malignant syndrome, navigate critical drug-drug interactions
involving CYP450 enzymes, and individualize therapy for vulnerable populations including children and older
adults. The 100-question multiple-choice format prepares advanced practice nursing students to integrate
neuropsychopharmacologic science with clinical judgment, ensuring safe, effective medication management for
patients with mental health and neurologic conditions.
SECTION ONE
Question 1
A 32-year-old patient with major depressive disorder is started on fluoxetine 20 mg daily. After one week, the
patient reports feeling more anxious and jittery. The nurse practitioner's most appropriate response is:
A. Discontinue fluoxetine immediately
B. Reassure the patient that activation and increased anxiety can occur early in SSRI treatment and typically
resolves within one to two weeks
C. Double the dose to achieve a faster response
D. Switch immediately to a different class of antidepressant
🟢 Correct Answer: B
🔴 RATIONALE: Transient jitteriness, anxiety, and activation can occur early in SSRI therapy before therapeutic
benefits are realized. This is not an indication to stop treatment. Reassurance and monitoring are appropriate.
,The onset of therapeutic effect typically takes 2-4 weeks, and full response may take 8-12 weeks. Dose increases
should follow a standard titration schedule.
Question 2
A patient with treatment-resistant depression has failed two adequate trials of SSRIs. The nurse practitioner is
considering adding aripiprazole. This augmentation strategy is supported because aripiprazole:
A. Increases serotonin and norepinephrine reuptake inhibition
B. Is a dopamine D2 and serotonin 5-HT1A partial agonist, and is FDA-approved as an adjunct for treatment-
resistant depression
C. Is a monoamine oxidase inhibitor
D. Is a tricyclic antidepressant
🟢 Correct Answer: B
🔴 RATIONALE: Aripiprazole, brexpiprazole, and quetiapine XR are atypical antipsychotics with FDA approval as
adjunctive therapy to antidepressants for treatment-resistant major depressive disorder. Their unique receptor
profiles, particularly partial agonism at D2 and 5-HT1A receptors, are thought to enhance antidepressant
effects.
Question 3
, A patient with generalized anxiety disorder is prescribed paroxetine. The nurse practitioner explains that the
therapeutic onset for anxiety relief is typically:
A. Immediate, within hours of the first dose
B. Within 1-2 days
C. Delayed, often requiring 2-4 weeks or longer for significant improvement
D. Only after 6 months of continuous treatment
🟢 Correct Answer: C
🔴 RATIONALE: Like depression, the anti-anxiety effect of SSRIs is delayed. While some patients may
experience early relief, significant, sustained improvement typically requires 2-4 weeks or more. This is due to
the time required for receptor downregulation, neuroplastic changes, and the modulation of neural circuits
involved in anxiety.
Question 4
A patient taking phenelzine (an MAOI) for depression develops a severe throbbing headache, nausea, and a
blood pressure of 210/120 mmHg after eating aged cheese. The nurse practitioner recognizes this as a:
A. Serotonin syndrome
B. Tyramine-induced hypertensive crisis
C. Neuroleptic malignant syndrome
D. Common side effect of phenelzine
QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines |
Graded A+...
CORE DOMAINS
Pharmacotherapy of Psychiatric Disorders: Antidepressants, Anxiolytics, and Mood Stabilizers
Pharmacology of the Central Nervous System: Antipsychotics and Agents for Neurodegenerative Disorders
Pain Management: Opioid and Non-Opioid Analgesics, Adjuvant Analgesics, and Substance Use Disorders
Pharmacotherapy of Neurologic Disorders: Antiepileptics, Antimigraine Agents, and Movement Disorders
Special Populations: Pediatric and Geriatric Psychopharmacology
Toxicology, Overdose Management, and Substance Use Disorder Pharmacotherapy
Pharmacokinetic Drug Interactions in Psychopharmacology and Neurology
Principles of Monitoring and Managing Adverse Effects of CNS-Active Drugs
INTRODUCTION
This comprehensive assessment is designed to evaluate advanced pharmacotherapeutic knowledge and clinical
reasoning skills essential for the safe and effective management of psychiatric and neurologic conditions in
primary and specialty care. The examination challenges candidates to apply principles of neuropharmacology,
receptor theory, and evidence-based prescribing to complex clinical scenarios involving depression, anxiety,
psychosis, epilepsy, pain, and substance use disorders. Through scenario-based testing, candidates must
,demonstrate the ability to select first-line pharmacotherapy, anticipate and manage serious adverse drug reactions
including serotonin syndrome and neuroleptic malignant syndrome, navigate critical drug-drug interactions
involving CYP450 enzymes, and individualize therapy for vulnerable populations including children and older
adults. The 100-question multiple-choice format prepares advanced practice nursing students to integrate
neuropsychopharmacologic science with clinical judgment, ensuring safe, effective medication management for
patients with mental health and neurologic conditions.
SECTION ONE
Question 1
A 32-year-old patient with major depressive disorder is started on fluoxetine 20 mg daily. After one week, the
patient reports feeling more anxious and jittery. The nurse practitioner's most appropriate response is:
A. Discontinue fluoxetine immediately
B. Reassure the patient that activation and increased anxiety can occur early in SSRI treatment and typically
resolves within one to two weeks
C. Double the dose to achieve a faster response
D. Switch immediately to a different class of antidepressant
🟢 Correct Answer: B
🔴 RATIONALE: Transient jitteriness, anxiety, and activation can occur early in SSRI therapy before therapeutic
benefits are realized. This is not an indication to stop treatment. Reassurance and monitoring are appropriate.
,The onset of therapeutic effect typically takes 2-4 weeks, and full response may take 8-12 weeks. Dose increases
should follow a standard titration schedule.
Question 2
A patient with treatment-resistant depression has failed two adequate trials of SSRIs. The nurse practitioner is
considering adding aripiprazole. This augmentation strategy is supported because aripiprazole:
A. Increases serotonin and norepinephrine reuptake inhibition
B. Is a dopamine D2 and serotonin 5-HT1A partial agonist, and is FDA-approved as an adjunct for treatment-
resistant depression
C. Is a monoamine oxidase inhibitor
D. Is a tricyclic antidepressant
🟢 Correct Answer: B
🔴 RATIONALE: Aripiprazole, brexpiprazole, and quetiapine XR are atypical antipsychotics with FDA approval as
adjunctive therapy to antidepressants for treatment-resistant major depressive disorder. Their unique receptor
profiles, particularly partial agonism at D2 and 5-HT1A receptors, are thought to enhance antidepressant
effects.
Question 3
, A patient with generalized anxiety disorder is prescribed paroxetine. The nurse practitioner explains that the
therapeutic onset for anxiety relief is typically:
A. Immediate, within hours of the first dose
B. Within 1-2 days
C. Delayed, often requiring 2-4 weeks or longer for significant improvement
D. Only after 6 months of continuous treatment
🟢 Correct Answer: C
🔴 RATIONALE: Like depression, the anti-anxiety effect of SSRIs is delayed. While some patients may
experience early relief, significant, sustained improvement typically requires 2-4 weeks or more. This is due to
the time required for receptor downregulation, neuroplastic changes, and the modulation of neural circuits
involved in anxiety.
Question 4
A patient taking phenelzine (an MAOI) for depression develops a severe throbbing headache, nausea, and a
blood pressure of 210/120 mmHg after eating aged cheese. The nurse practitioner recognizes this as a:
A. Serotonin syndrome
B. Tyramine-induced hypertensive crisis
C. Neuroleptic malignant syndrome
D. Common side effect of phenelzine
